title: The dawn of hedgehog inhibitors: Vismodegib.
abstract: Cancer, one of the leading causes of death worldwide is estimated to increase to approximately 13.1 million by 2030. This has amplified the research in oncology towards the exploration of novel targets. Recently there has been lots of interest regarding the hedgehog (Hh) pathway, which plays a significant role in the development of organs and tissues during embryonic and postnatal periods. In a normal person, the Hh signaling pathway is under inhibition and gets activated upon the binding of Hh ligand to a transmembrane receptor called Patched (PTCH1) thus allowing the transmembrane protein, smoothened (SMO) to transfer signals through various proteins. One of the newer drugs namely vismodegib involves the inhibition of Hh pathway and has shown promising results in the treatment of advanced basal-cell carcinoma as well as medulloblastoma. It has been granted approval by US Food and Drug Administration's (US FDA) priority review program on January 30, 2012 for the treatment of advanced basal-cell carcinoma. The drug is also being evaluated in malignancies like medulloblastoma, pancreatic cancer, multiple myeloma, chondrosarcoma and prostate cancer. Moreover various Hh inhibitors namely LDE 225, saridegib, BMS 833923, LEQ 506, PF- 04449913 and TAK-441 are also undergoing phase I and II trials for different neoplasms. Hence this review will describe briefly the Hh pathway and the novel drug vismodegib.
authors: Division of Clinical Pharmacology, Jawaharlal Institute of Postgradute Medical Education and Research, Puducherry, India.
authors: Selvarajan
authors: S
authors: Sandhiya
authors: George
authors: G
authors: Melvin
authors: Srinivasamurthy Suresh
authors: SS
authors: Kumar
authors: Steven Aibor
authors: SA
authors: Dkhar
keywords: Advanced basal-cell carcinoma; hedgehog pathway; medulloblastoma
references: Science. 2009 Oct 23;326(5952):572-4
references: 19726788
references: N Engl J Med. 2009 Sep 17;361(12):1173-8
references: 19726761
references: Clin Cancer Res. 2011 Sep 1;17(17):5774-82
references: 21753154
references: Br J Dermatol. 2005 Jan;152(1):43-51
references: 15656799
references: Clin Cancer Res. 2010 Jun 15;16(12):3130-40
references: 20530699
references: Clin Cancer Res. 2011 Apr 15;17(8):2512-20
references: 21300760
references: J Natl Cancer Inst. 2008 May 21;100(10):692-7
references: 18477794
references: Clin Cancer Res. 2011 Apr 15;17(8):2071-3
references: 21367749
references: Head Neck Oncol. 2009 Mar 02;1:6
references: 19284526
references: Nat Genet. 2002 Jul;31(3):306-10
references: 12068298
references: Clin Cancer Res. 2011 Apr 15;17(8):2502-11
references: 21300762
references: Cancer Res. 2004 Sep 1;64(17):6071-4
references: 15342389
references: Semin Oncol. 2012 Apr;39(2):139-44
references: 22484185
references: N Engl J Med. 2012 Jun 7;366(23):2171-9
references: 22670903
references: Nat Rev Drug Discov. 2012 Mar 30;11(4):257-8
references: 22460111
references: Nature. 1980 Oct 30;287(5785):795-801
references: 6776413
references: Vitam Horm. 2012;88:461-72
references: 22391316
references: Int J Mol Med. 2012 Mar;29(3):423-7
references: 22138977
references: J Cell Sci. 2002 Dec 1;115(Pt 23):4393-7
references: 12414986
references: Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):5924-8
references: 17062662
references: Nat Biotechnol. 2012 Mar 07;30(3):203
references: 22398601
references: N Engl J Med. 2009 Sep 17;361(12):1164-72
references: 19726763
references: Mini Rev Med Chem. 2011 Mar;11(3):200-13
references: 21222574